This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
In August 2022, Lee and Lifeson returned to the stage at the South Park 25th anniversary concert at Red Rocks Amphitheatre, with South Park's co-creator Matt Stone on drums to perform "Closer to the Heart" alongside the members of Primus; this was their first performance since the death of Peart. In September 2022, Lee and Lifeson performed at the London Taylor Hawkins tribute concert with Dave Grohl and Omar Hakim on drums. They performed "2112: Overture", "Working Man", and "YYZ", the latter of which was Hawkins' favourite Rush song. Later in September 2022, Lee and Lifeson played the same set at the second Taylor Hawkins Tribute show in Los Angeles. Grohl was the drummer again on "2112", Chad Smith of the Red Hot Chili Peppers joined them for "Working Man", and Danny Carey from Tool played drums for "YYZ". Those appearances fuelled speculation over a possible Rush reunion, with Paul McCartney (who attended the Hawkins tribute shows) urging Lee and Lifeson to tour again, and Smith commenting, "Those guys are so happy to be playing again... They were part of the show. They loved it and enjoyed the hell out of it. Those guys miss playing.
== References == Allen, Ira (1969) [1798]. The natural and political history of the State of Vermont, one of the United States of America. Charles E. Tuttle Company. ISBN 0-8048-0419-2. Cooper, Grace Rogers (1973). Thirteen Star Flags (PDF). Smithsonian Institution Press. Archived (PDF) from the original on 2022-10-09. Tuttle, Mrs. George F. (1909). 300 Years In The Champlain Valley. Saranac, NY: Daughters of the American Revolution. Van de Water, Frederic Franklyn (1974). The Reluctant Republic: Vermont 1724–1791. The Countryman Press. ISBN 0-914378-02-3. Shalhope, Robert. (1996). Bennington and the Green Mountain Boys: The Emergence of Liberal Democracy in Vermont, 1760-1850. Johns Hopkins University Press
Another recent system divides all cephalopods into two clades. One includes nautilus and most fossil nautiloids. The other clade (Neocephalopoda or Angusteradulata) is closer to modern coleoids, and includes belemnoids, ammonoids, and many orthocerid families. There are also stem group cephalopods of the traditional Ellesmerocerida that belong to neither clade. The coleoids, despite some doubts, appear from molecular data to be monophyletic.
{\displaystyle \sigma _{11}=\left(\lambda ^{2}-{\cfrac {1}{\lambda ^{2}}}\right)\left({\cfrac {\mu J_{m}}{J_{m}-I_{1}+3}}\right)~;~~\sigma _{22}=0~;~~\sigma _{33}=\left(1-{\cfrac {1}{\lambda ^{2}}}\right)\left({\cfrac {\mu J_{m}}{J_{m}-I_{1}+3}}\right)~.}
=== Grade === Like some other cancers, sarcomas are assigned a grade (low, intermediate, or high) based on the appearance of the tumor cells under a microscope. In general, grade refers to how aggressive the cancer is and how likely it is to spread to other parts of the body ("metastasize"). Low-grade sarcomas have a better prognosis than higher-grade sarcomas, and are usually treated surgically, although sometimes radiation therapy or chemotherapy are used. Intermediate- and high-grade sarcomas are more frequently treated with a combination of surgery, chemotherapy, or radiation therapy. Since high-grade tumors are more likely to undergo metastasis (invasion and spread to locoregional and distant sites), they are treated more aggressively. The recognition that many sarcomas are sensitive to chemotherapy has dramatically improved the survival of patients. For example, in the era before chemotherapy, long-term survival for pediatric patients with localized osteosarcoma was only about 20%, but now has risen to 60–70%.
Sources: en.wikipedia.org
=== Diabetes mellitus === GCK mutations reduce the functional efficiency of the glucokinase molecule. Heterozygosity for alleles with reduced enzyme activity results in a higher threshold for insulin release and persistent, mild hyperglycemia. This condition is referred to as maturity onset diabetes of the young, type 2 (MODY2). The most recent overview of GCK mutation that were observed in patients claims 791 mutations, of which 489 are thought to cause the MODY diabetes and therefore reduce the functional efficiency of the glucokinase molecule. Homozygosity for GCK alleles with reduced function can cause severe congenital insulin deficiency, resulting in persistent neonatal diabetes.
=== Primary sources === Craig, Frederick Walter Scott, ed. (1975). British General Election Manifestos, 1900–74. Springer. Liberal Magazine 1901 in-depth coverage of 1900. Liberal Magazine 1900 in-depth coverage of 1899. The Liberal year book. 1887 (1887) online The Liberal year book: 1906 (1906); online The Liberal year book: 1907 (1907); online The Liberal Year Book: 1908 (1908); online, Biographies and voting returns since 1880s.
== Chemistry == Selenocysteine is the Se-analogue of cysteine. It is rarely encountered outside of living tissue (nor is it available commercially) because of its high susceptiblility to air-oxidation. More common is the oxidized derivative selenocystine, which has an Se-Se bond. Both selenocysteine and selenocystine are white solids. The Se-H group is more acidic (pKa = 5.43) than the thiol group; thus, it is deprotonated at physiological pH.
{\displaystyle (\mathbf {u} _{1}\times \mathbf {u} _{2})\times (\mathbf {u} _{2}\times \mathbf {u} _{3})=[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{1}]\mathbf {u} _{2}-[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{2}]\mathbf {u} _{1}=[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{1}]\mathbf {u} _{2}}
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.